In this video, Amit Bar-Or, MD, FRCPC, gives an overview of encouraging findings regarding the long-term safety of ozanimod for relapsing forms of multiple sclerosis.
In this video, Amit Bar-Or, MD, FRCPC, discusses new long-term data that show a favorable safety profile over time with the use of ozanimod among patients with relapsing forms of multiple sclerosis.
In this video, Stewart Tepper, MD, discusses the findings from his recent trial on the long-term efficacy of erenumab among patients with chronic migraine with or without acute medication overuse, and how erenumab has changed the way he practices.
In this video, Dr Buse discusses the findings of the OVERCOME Study, in which she and her colleagues investigated the influence of acute treatment optimization on disability and health-related quality of life among people with migraine.
In this video, Dr Patel discusses the findings from his study on the the role of triggers in status migrainosus and its association with morbidity. This study was featured in the 2020 American Academy of Neurology Science Highlights.
In this podcast, Dr Charvet and Dr Eilam-Stock discuss the findings from their study, which provided evidence of early neuropsychological markers of cognitive involvement among patients with multiple sclerosis.
Neeta Garg, MD, on Neurological Diagnostic Testing Among Elderly Adults With Acute Altered Mental Status
In this podcast, Dr Garg discusses the findings from her recent study on neurological diagnostic testing among elderly adult patients with acute altered mental status. This study was featured in the 2020 American Academy of Neurology Science Highlights.
In your practice, how do you ensure that treatment is optimized for your patients with migraine? Let us know by taking our poll.
Cognitive changes are common among people with multiple sclerosis (MS). How do you screen for cognitive involvement among your patients with MS? Let us know by taking our poll.
For the initial treatment of pediatric multiple sclerosis, do you choose to treat your patients with newer or injectable disease-modifying therapies?